VJOncology is committed to improving our service to you

ASCO 2020 | JAVELIN Bladder 100: avelumab maintenance

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives us an update on the JAVELIN Bladder 100 study (NCT02603432) in urothelial carcinoma. This study that compared maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter